Back to Newsroom

Arbutus to Present HBV Data at 2017 AASLD Liver Meeting

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 03, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at The Liver Meeting® 2017 organized by the American Association for the Study of Liver Diseases (AASLD) to be held on October 20 – 24, 2017 at the Walter E. Washington Convention Center in Washington, DC.